| __timestamp | Apellis Pharmaceuticals, Inc. | Bio-Techne Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 8379522 | 30945000 |
| Thursday, January 1, 2015 | 13730311 | 40853000 |
| Friday, January 1, 2016 | 22978599 | 45187000 |
| Sunday, January 1, 2017 | 40303878 | 53514000 |
| Monday, January 1, 2018 | 105285576 | 55329000 |
| Tuesday, January 1, 2019 | 220968770 | 62413000 |
| Wednesday, January 1, 2020 | 299921000 | 65192000 |
| Friday, January 1, 2021 | 420869000 | 70603000 |
| Saturday, January 1, 2022 | 387236000 | 87140000 |
| Sunday, January 1, 2023 | 354387000 | 92493000 |
| Monday, January 1, 2024 | 96664000 |
Igniting the spark of knowledge
In the ever-evolving world of biotechnology, research and development (R&D) is the lifeblood of innovation. Over the past decade, Apellis Pharmaceuticals, Inc. and Bio-Techne Corporation have demonstrated contrasting R&D investment strategies. Apellis Pharmaceuticals has shown a remarkable growth trajectory, with R&D expenses increasing by over 4,000% from 2014 to 2023. This surge underscores their commitment to pioneering new treatments and therapies. In contrast, Bio-Techne Corporation has maintained a steady increase in R&D spending, with a 200% rise over the same period, reflecting a more consistent approach to innovation.
While Apellis's R&D expenses peaked in 2021, Bio-Techne's investment continued to grow, reaching its highest in 2023. This divergence highlights the varied strategies companies employ to stay competitive in the biotech sector. As we look to the future, these trends offer valuable insights into the dynamic landscape of biotech innovation.
R&D Spending Showdown: AbbVie Inc. vs Bio-Techne Corporation
Research and Development Expenses Breakdown: Bristol-Myers Squibb Company vs Apellis Pharmaceuticals, Inc.
R&D Spending Showdown: Regeneron Pharmaceuticals, Inc. vs Bio-Techne Corporation
Research and Development Expenses Breakdown: Teva Pharmaceutical Industries Limited vs Apellis Pharmaceuticals, Inc.
Dr. Reddy's Laboratories Limited or Bio-Techne Corporation: Who Invests More in Innovation?
Operational Costs Compared: SG&A Analysis of Bio-Techne Corporation and Apellis Pharmaceuticals, Inc.
Analyzing R&D Budgets: Bio-Techne Corporation vs Geron Corporation
Comparing Innovation Spending: Bio-Techne Corporation and Galapagos NV
Analyzing R&D Budgets: Bio-Techne Corporation vs Taro Pharmaceutical Industries Ltd.
Apellis Pharmaceuticals, Inc. vs Perrigo Company plc: Strategic Focus on R&D Spending
R&D Spending Showdown: Apellis Pharmaceuticals, Inc. vs HUTCHMED (China) Limited
Analyzing R&D Budgets: Apellis Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.